Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer

In conclusion, recurrences appear to be more common in patients with gastrointestinal and gynecological cancer and major bleedings in patients with genitourinary and gastrointestinal cancer. Oral apixaban is a valid oral alternative to subcutaneous dalteparin for the treatment of a large spectrum of patients with cancer-associated VTE.PMID:34530482 | DOI:10.1055/s-0041-1735194

Source: Thrombosis and Haemostasis - September 16, 2021 Category: Hematology Authors: Giancarlo Agnelli Andr és Muñoz Laura Franco Isabelle Mah é Benjamin Brenner Jean M Connors Gualberto Gussoni Eva N Hamulyak Catherine Lambert Maria Rosales Suero Rupert Bauersachs Adam Torbicki Cecilia Becattini Source Type: research